Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia (Annals of Hematology, (2018), 10.1007/s00277-018-3229-5)

  1. Martínez-Cuadrón, D.
  2. Boluda, B.
  3. Martínez, P.
  4. Bergua, J.
  5. Rodríguez-Veiga, R.
  6. Esteve, J.
  7. Vives, S.
  8. Serrano, J.
  9. Vidriales, B.
  10. Salamero, O.
  11. Cordón, L.
  12. Sempere, A.
  13. Jiménez-Ubieto, A.
  14. Prieto-Delgado, J.
  15. Díaz-Beyá, M.
  16. Garrido, A.
  17. Benavente, C.
  18. Pérez-Simón, J.A.
  19. Moscardó, F.
  20. Sanz, M.A.
  21. Montesinos, P.
Aldizkaria:
Annals of Hematology

ISSN: 1432-0584,  0939-5555

Argitalpen urtea: 2018

Alea: 97

Zenbakia: 5

Orrialdeak: 923

Mota: Hutsen zuzenketa

DOI: 10.1007/S00277-018-3277-X GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus